ArriVent BioPharma (AVBP) announced that its Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC did not meet the primary endpoint of progression-free survival by BICR. Clinical benefit was observed in secondary endpoints. The stock was halted pending the news.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
